IMNM Immunome Inc.: institutional ownership and insider trading
214 funds reported holding $2.66B of Immunome Inc. in their latest 13F filings; in Q2 2026 funds net bought $19.0M, with 29 new positions and 28 funds selling out; over the last 12 months insiders bought $2.31M and sold $27.5M on the open market; over its last four quarters it reported revenue of $0 and net income of −$254M.
IMNM revenue and earnings
- Quarter ended Jun 30, 2026: revenue $0, net income −$73.1M, EPS -0.65
- Quarter ended Mar 31, 2026: revenue $0, net income −$53.8M, EPS -0.48
- Quarter ended Dec 31, 2025: revenue $0, net income −$69.9M, EPS -0.76
- Quarter ended Sep 30, 2025: revenue $0, net income −$57.5M, EPS -0.65
Famous investors holding IMNM
- Renaissance Technologies (Renaissance Technologies): $5.32M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $6.43M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $507K, 0.0% of the portfolio
Largest institutional holders of IMNM
- T. Rowe Price Investment Management, Inc. — $417M
- FMR LLC — $360M
- BlackRock, Inc. (BLK) — $187M
- VANGUARD GROUP INC — $130M
- STATE STREET CORP (STT, STT-PG) — $116M
- WELLINGTON MANAGEMENT GROUP LLP — $110M
- Redmile Group, LLC — $104M
- PRIMECAP MANAGEMENT CO/CA/ — $97.1M
- VANGUARD CAPITAL MANAGEMENT LLC — $96.4M
- DRIEHAUS CAPITAL MANAGEMENT LLC — $92.1M
Recent IMNM insider trades
- Sep 11, 2026: Higgins Jack sold 13,200 shares ($334K)
- Aug 12, 2026: Barchas Isaac sold 83,464 shares ($2.20M)
- Aug 7, 2026: Barchas Isaac sold 36,088 shares ($940K)
- Aug 4, 2026: Horn Kinney sold 90,616 shares ($2.27M)
5%+ owners
- T. Rowe Price Investment Management, Inc.: 17.4% (Schedule 13G/A, filed Aug 14, 2026)